Bruker (BKD) Stock Price & Analysis
BKD Stock Chart & Stats
- Day’s Range
- EUR 50.88 - EUR 55.37
- 52-Week Range
- EUR 28.35 - EUR 58.59
- Previous Close
- EUR 55.51
- Volume
- 160
- Average Volume (3M)
- 22
- Market Cap
- EUR 7.79B
- Enterprise Value
- EUR 10.82B
- Total Cash (Recent Filing)
- EUR 184.90M
- Total Debt (Recent Filing)
- EUR 1.92B
- Price to Earnings (P/E)
- ―
- Beta
- 0.62
- Next Earnings
- Nov 04, 2026 (Est.)
- EPS Estimate
- 0.38
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 0.35%
Bulls Say, Bears Say
Bulls Say
Recurring Installed-base Revenue
Bruker combines upfront instrument sales with recurring service, software, maintenance, and consumables revenue. This installed-base model can support customer retention, improve revenue visibility, and provide ongoing monetization beyond each instrument’s initial sale.
Strong Scientific Instrument Demand
Sustained bookings growth and a book-to-bill ratio above one indicate demand is exceeding recognized segment revenue and supporting backlog formation. This provides a durable foundation for future sales, although conversion depends on delivery timing and customer budgets.
Cost-savings Execution
The scale and execution of Bruker’s cost program can strengthen operating leverage as revenue recovers. Realized savings already provide evidence of implementation, while the additional planned reductions could support more durable margin improvement and earnings growth.
Bears Say
Profitability Deterioration
The shift from substantial profitability to net losses, alongside sharply lower operating margins, shows that revenue growth has not translated reliably into earnings. Persistent margin pressure could reduce internal funding capacity and make the recovery dependent on successful cost control.
Regional And Customer Weakness
Weakness across China, broader Asia Pacific, and U.S. academic customers creates a meaningful demand headwind for Bruker’s research-oriented businesses. If these end-market pressures persist, they could restrain organic growth and delay recovery in affected segments.
Delayed Deep-tech Revenue Conversion
Long delivery cycles mean strong deep-tech bookings may not translate into revenue or cash generation quickly. This creates a structural timing gap between demand capture and financial realization, leaving near-term growth dependent on other businesses and successful execution.
Bruker News
BKD FAQ
What was Bruker’s price range in the past 12 months?
What is Bruker’s market cap?
When is Bruker’s upcoming earnings report date?
How were Bruker’s earnings last quarter?
Is Bruker overvalued?
Does Bruker pay dividends?
What is Bruker’s EPS estimate?
How many shares outstanding does Bruker have?
What happened to Bruker’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Bruker?
What is the TipRanks Smart Score and how is it calculated?
Bruker Stock Smart Score
Company Description
Bruker
Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Frank H. Laukien
- Employees
- 11,085
- Website
- www.bruker.com
- Address
- 40 Manning Road, Billerica, MA, 01821, US
Bruker (BKD) Earnings & Revenues
BKD Company Deck
BKD Earnings Call
Earnings Call SentimentPositive
The call showed material operational and financial progress — notably a return to organic growth in Q2, substantial margin expansion, double-digit non-GAAP EPS growth, strong deep-tech and semiconductor bookings, and confirmed cost-savings execution and year guidance. However, material lowlights included a $135M goodwill impairment leading to a GAAP loss, lingering weakness in U.S. academic/government spending, regional softness in China and APAC, timing-related revenue recognition delays from longer lead-time deep tech orders, and FX/tariff headwinds. On balance the positive momentum in bookings, margins, cash flow and cost savings, along with maintained FY guidance, outweigh the notable one-time impairment and near-term timing/currency headwinds.
View all DE:BKD earnings summariesBKD Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 5 | 11 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 3 | 0 | 9 |
